Navigation Links
NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate
Date:12/22/2010

ROCKVILLE, Md., Dec. 22, 2010 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) and scientists at the University of Massachusetts Medical School, led by Dr. Trudy Morrison, published in the January 2011 issue of The Journal of Virology, a report indicating that a novel virus-like particle (VLP) vaccine candidate against respiratory syncytial virus (RSV) protects mice from a live virus challenge.  This vaccine candidate has been created with technology that Novavax has licensed exclusively from the University of Massachusetts Medical School.  

The publication describes the production and testing of a novel RSV VLP vaccine candidate. Immunization with this genetically engineered RSV VLP vaccine stimulated immune response against key vaccine targets, the RSV G attachment and RSV F fusion proteins. The antibody responses achieved with this vaccine candidate were equal to or better than levels resulting from infection with live RSV. This RSV G+F VLP vaccine stimulated both anti-G and anti-F protein serum antibodies typical of a more Th1-biased response characteristic of natural infection with RSV.  When challenged with live RSV, animals immunized with RSV VLPs were completely protected from replication of the virus in the lungs and showed no signs of enhanced respiratory disease.

"This study indicates that immunization with a VLP vaccine results in functional and protective immune responses against RSV.  Induction of such functional, protective immunity has been a key challenge in RSV vaccine development.  RSV is the leading global cause of infant and childhood respiratory disease, and these encouraging preclinical safety and efficacy data suggest that an RSV VLP vaccine is a promising approach and should be developed further," said Greg Glenn, M.D., Novavax's Chief Scientific Officer.

About Respiratory Syncytial Virus

RS
'/>"/>

SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NOVAVAX Awarded Nearly $1 Million in Grants from IRS Under Qualifying Therapeutic Discovery Project
2. NOVAVAX to Present at the Immunotherapeutics and Vaccine (IMVAC) Summit
3. NOVAVAX Elects Richard H. Douglas to its Board of Directors
4. Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer
5. Novavax Announces Manufacturing Management Appointments
6. Novavax Announces Publication of a Pre-clinical Study with its Pandemic 2009 H1N1 Influenza Virus-Like Particle (VLP) Vaccine
7. NOVAVAX Completes Enrollment of Pivotal H1N1 Influenza Vaccine Clinical Trial in Mexico
8. NOVAVAX to Present at the 12th Annual BIO CEO & Investor Conference
9. NOVAVAX to Present at Phacilitate Vaccine Forum Washington 2010
10. NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate
11. NOVAVAX to Present at the Piper Jaffray 21st Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 Date: ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, ... only national nonprofit organization solely dedicated to finding a cure ... those affected worldwide, will host its annual Crystal Ball on ...
(Date:1/14/2014)... provider of strategic communications services to corporations and organizations preparing for ... United States and Europe , today ... to the firm,s Washington, D.C. office. ... years of service as Associate Commissioner for the Office of External ...
(Date:1/14/2014)... Texas , Jan. 14, 2014 The ... and research medicinal plants and therapeutic derivatives thereof ... health professionals, and researchers about the challenges of ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... , FREISING-WEIHENSTEPHAN, Germany , ... preclinical data for its proprietary PRS-110 Anticalin(R),compound, which targets ... in a xenograft mouse model. The results provide an,indication ... may,be of significant therapeutic value in treating cancer. A ...
... ... supplies irrigation management solutions. The company was approved for $250,000 for completion and commercialization ... plant is the sensor™.” , ... (Vocus) April 30, 2010 -- Smartfield, Inc. is ...
... DENVER , April 29 HEALTHeCAREERS Network , ... and career resources. , , ...   http://www.newscom.com/cgi-bin/prnh/20100204/FL49504LOGO-a ) , , ... The Society for Cardiovascular Angiography and Interventions (SCAI) recently joined the Network, ...
Cached Biology Technology:Pieris Announces Positive Preclinical Data on c-Met Anticalin Drug Program 2$250,000 Awarded to Smartfield, Inc. of Lubbock, TX by the Texas Emerging Technology Fund 2Healthcare Web site Expands Reach to Cardiology Professionals 2Healthcare Web site Expands Reach to Cardiology Professionals 3
(Date:4/17/2014)... professor Rajendra Singh Thursday as a "Champion of ... solar deployment in the residential, commercial and industrial ... of Electrical and Computer Engineering and director of ... local hero leading the charge across the country ... power and driving policy changes at the local ...
(Date:4/17/2014)... novel method to help kidney stone sufferers ensure ... possible., Kidney stones represent a major medical problem ... untreated, apart from being particularly painful, they can ... many patients treated successfully, stone recurrence is also ... to diagnosis and treatment needs to be identified ...
(Date:4/17/2014)... University researchers have detected new early-warning signs of the ... could have far-reaching implications for the diagnosis and treatment ... 25 million Americans. , "We had not expected to ... early stages," said Ann Elsner, professor and associate dean ... of the study. "We set out to study the ...
Breaking Biology News(10 mins):White House honors Clemson professor as 'Champion of Change' for solar deployment 2New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... Dangerous disease often spreads faster than it takes to ... at Kansas State University have developed a test to ... Sanjeev Narayanan, assistant professor, and Greg Peterson, research microbiologist, ... use a device called a DNA spotted microarray to ...
... double-stranded DNA into the space of a typical chromosome, ... genetic material it contains. "It is like compacting ... Professor Emeritus in Physics at the University of Chicago. ... is showing that these and related organisms may have ...
... D.C. (August 21, 2008) The Aplastic Anemia ... patients that the U.S. Food & Drug Administration (FDA) ... data from the AZA-001 trial, which found that Vidaza ... (myelodysplastic syndromes) patients. Vidaza was also shown to delay ...
Cached Biology News:Rapid test for pathogens developed by K-State researchers 2Exploding chromosomes fuel research about evolution of genetic storage 2Exploding chromosomes fuel research about evolution of genetic storage 3
... This kit allows for quick and reproducible immunoprecipitation ... The system is more reproducible than regular IPs, ... protein A/G agarose without disrupting the agarose bed. ... and Release is reversible, and elution of the ...
... Polyclonal Antibody, Unconjugated ... a dilution of 1/100. IP: Use ... Use at an assay dependent dilution. ... tested in other applications. Optimal ...
Membrane Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
... Using multicolor analysis in a modern flow ... cells that are differentially labeled with fluorescent ... dyes typically used for cell labeling are ... by a flow cytometers filters. Thus, the ...
Biology Products: